Back to search

Article

Real-World Serum Neurofilament Light Chain and GFAP in Amyotrophic Lateral Sclerosis on a Commercial ECLIA Platform

2026-06-26

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Neurofilament light chain (NfL) is an established prognostic biomarker in amyotrophic lateral sclerosis (ALS): SIMOA-based studies show that baseline serum NfL predicts ALSFRS-R slope and survival and serves as an outcome measure in clinical trials. The commercial Roche Elecsys electrochemiluminescence immunoassay (ECLIA) reads 6-to 8-fold lower than SIMOA, and its clinical...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5deb18e1-0bb2-574d-8251-2038cd4c9726
DOI
10.64898/2026.06.24.26356370
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-World Serum Neurofilament Light Chain and GFAP in Amyotrophic Lateral Sclerosis on a Commercial ECLIA PlatformDOI 10.64898/2026.06.24.26356370
Prognostic Clinical and Biological Markers for Amyotrophic Lateral Sclerosis Disease Progression: Validation and Implications for Clinical Trial Design and AnalysisSemantic proximity
Emerging biomarkers in amyotrophic lateral sclerosis: from pathogenesis to clinical applicationsSemantic proximity
Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapiesSemantic proximity
Comprehensive cross-sectional and longitudinal comparisons of plasma glial fibrillary acidic protein and neurofilament light across FTD spectrum disordersSemantic proximity
Molecular Biomarkers in Neurological Diseases: Advances in Diagnosis and PrognosisSemantic proximity
Plasma Neurofilament Light Chain and Clinical Diagnosis in Frontotemporal Dementia SyndromesSemantic proximity
Plasma neurofilament light levels show elevation two years prior to diagnosis of amyotrophic lateral sclerosis in the UK BiobankSemantic proximity
Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.Semantic proximity
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease ProgressionSemantic proximity
Plasma neurofilament light levels show elevation prior to diagnosis of sporadic motor neuron disease in the UK Biobank cohortSemantic proximity
Population-based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral SclerosisSemantic proximity
<span class="word">Longitudinal <span class="word allCaps">CSF <span class="word">and <span class="word">Serum <span class="word">Biomarker <span class="word">Dynamics <span class="word">in <span class="word">Tofersen <span class="word"><span class="changedDisabled">Treated <span class="word">SOD1-<span class="word allCaps">ALS: <span class="word"><span class="changedDisabled">A <span class="word"><span class="changedDisabled">Real-<span class="word"><span class="changedDisabled">World <span cl…Semantic proximity
Select a neighboring publication to make it the new centre.